未名医药(002581) - 2025 Q2 - 季度业绩预告

Shandong Weiming Bio-Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast The company's 2025 semi-annual performance forecast indicates a significant expansion of net loss compared to the prior year Expected Performance for the Current Period The company expects to record a net loss for the first half of 2025, with the loss significantly expanding compared to the same period last year 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of the Listed Company | Loss: 55.00 million CNY - 85.00 million CNY | Loss: 29.6149 million CNY | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss: 53.00 million CNY - 83.00 million CNY | Loss: 26.9934 million CNY | | Basic Earnings Per Share | Loss: 0.0834 CNY/share - 0.1288 CNY/share | Loss: 0.0449 CNY/share | Communication with Accounting Firm The company explicitly states that the financial data in this performance forecast is a preliminary estimate and has not been audited by a certified public accountant - The financial data related to this performance forecast has not been audited by a certified public accountant[4] Explanation of Performance Changes The primary reason for the expanded loss is the suspension of production and sales activities by subsidiary Tianjin Weiming, leading to a significant year-over-year decline in net profit attributable to the parent company - Net profit attributable to the parent company decreased by 85.72% to 187.02% year-over-year during the reporting period, primarily due to the suspension of production and sales by subsidiary Tianjin Weiming[5] Other Relevant Information The company reminds investors that this performance forecast is a preliminary estimate by the finance department, and the final data will be subject to the 2025 semi-annual report to be disclosed, advising caution regarding investment risks - This performance forecast is a preliminary estimate by the company's finance department, unaudited, and the final data will be based on the 2025 semi-annual report, requiring investors to make cautious decisions[6]